Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $30M
Founded date: 2021
Investors 3
| Date | Name | Website |
| 10.06.2023 | F-Prime Ca... | fprimecapi... |
| 10.12.2021 | Atlas Vent... | atlasventu... |
| 28.05.2022 | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.12.2021 | Series A | $30M | Eight Road... |
Mentions in press and media 5
| Date | Title | Description |
| 29.06.2023 | K36 Therapeutics raises $70M in Series B to fund multiple myeloma research | - |
| 28.06.2023 | K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Trans... | - |
| 27.12.2022 | Our Investment in Alternative Bio | Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financin... |
| 09.12.2021 | K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures | CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing breakthrough therapies for the unmet medical needs of cancer patients, announced today its $30 millio... |
| - | K36 Therapeutics | “Home | K36tx” |